Greenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Purchases $11,080.00 in Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSIGet Free Report) VP Jaye Thompson acquired 800 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The shares were acquired at an average cost of $13.85 per share, with a total value of $11,080.00. Following the completion of the transaction, the vice president now directly owns 263,148 shares in the company, valued at approximately $3,644,599.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jaye Thompson also recently made the following trade(s):

  • On Friday, August 2nd, Jaye Thompson bought 1,000 shares of Greenwich LifeSciences stock. The shares were bought at an average cost of $15.15 per share, with a total value of $15,150.00.
  • On Thursday, July 18th, Jaye Thompson purchased 1,000 shares of Greenwich LifeSciences stock. The stock was bought at an average cost of $16.00 per share, for a total transaction of $16,000.00.

Greenwich LifeSciences Trading Up 6.6 %

Shares of NASDAQ GLSI opened at $15.92 on Monday. The stock has a market capitalization of $205.05 million, a PE ratio of -22.11 and a beta of 1.61. Greenwich LifeSciences, Inc. has a twelve month low of $7.58 and a twelve month high of $21.44. The stock has a fifty day simple moving average of $14.68 and a 200-day simple moving average of $15.10.

Greenwich LifeSciences (NASDAQ:GLSIGet Free Report) last released its earnings results on Wednesday, August 14th. The company reported ($0.20) earnings per share for the quarter, meeting the consensus estimate of ($0.20). On average, equities analysts predict that Greenwich LifeSciences, Inc. will post -0.81 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright lifted their target price on shares of Greenwich LifeSciences from $36.00 to $38.00 and gave the company a “buy” rating in a report on Friday, August 23rd.

View Our Latest Stock Report on GLSI

Institutional Investors Weigh In On Greenwich LifeSciences

Large investors have recently added to or reduced their stakes in the business. Rhumbline Advisers purchased a new position in Greenwich LifeSciences in the 2nd quarter valued at approximately $117,000. Bank of New York Mellon Corp purchased a new stake in shares of Greenwich LifeSciences during the second quarter worth $264,000. Finally, Vanguard Group Inc. raised its stake in shares of Greenwich LifeSciences by 0.6% in the first quarter. Vanguard Group Inc. now owns 223,102 shares of the company’s stock valued at $4,449,000 after acquiring an additional 1,420 shares in the last quarter. 4.16% of the stock is owned by hedge funds and other institutional investors.

About Greenwich LifeSciences

(Get Free Report)

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.

Featured Articles

Insider Buying and Selling by Quarter for Greenwich LifeSciences (NASDAQ:GLSI)

Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.